Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

22. mars 2022 oppdatert av: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Retrospective Study With Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN (Squamous Cell Carcinoma of the Head and Neck): Real World Data.

Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Assignment of a patient to a specific therapeutic strategy has been already decided in the past according to normal routine clinical practice; the decision to prescribe a specific treatment (between January 2012 and December 2018) was clearly dissociated from the decision to include a patient in the present study.

The investigators will retrospectively collect the information for 500 patients diagnosed with recurrent and/or metastatic SCCHN treated with a cetuximab plus paclitaxel regimen as first line for unresectable recurrent and/or metastatic disease, starting treatment with the defined cetuximab plus paclitaxel regimen, in 20 hospital members of the "Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)", who express consent to participate in the study or have not explicitly withheld consent for use of their data. The information from the patients' medical records will be collected through the online database of the TTCC Group.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) with the restriction that the data collection will only be clinical data from patients who received paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab that could have been switched to biweekly during the maintenance phase.

The main objective will be to estimate the Progression-free survival (PFS) in patients treated with paclitaxel 80 mg/m2 as a starting dose, with weekly cetuximab that could have been switched to biweekly during the maintenance phase, as first line for recurrent and/or metastatic SCCHN.

Secondary objectives include:

To determine the Overall Response Rate (ORR), Best Overall Response (BOR), Disease Control Rate (DCR), overall survival (OS), duration of response (DoR), and safety in patients treated with the defined cetuximab plus paclitaxel regimen.

To evaluate the percentage of long disease-free survivors (defined as patients disease-free and alive at 2 years), and evaluate the percentage of long non-disease-free survivors (defined as patients not disease free, but alive at 2 years.

Analyses of patient outcomes by prognostic subgroups.

Studietype

Observasjonsmessig

Registrering (Faktiske)

531

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Spania
      • Barcelona, Spania, 08003
        • Hospital de Mar
      • Madrid, Spania, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Spania, 28040
        • Hospital Universitario Clinico San Carlos
      • Madrid, Spania, 28007
        • Hospital Universitario Gregorio Marañón
    • Andalucia
      • Granada, Andalucia, Spania, 18014
        • Hospital Universitario Virgen de las Nieves
      • Málaga, Andalucia, Spania, 29010
        • Hospital Regional Universitario de Málaga
      • Sevilla, Andalucia, Spania, 41014
        • Hospital Universitario Virgen de Valme
    • Aragon
      • Zaragoza, Aragon, Spania, 50009
        • Hospital Universitario Miguel Servet
    • Cantabria
      • Santander, Cantabria, Spania, 39008
        • Hospital Universitario Marqués de Valdecilla
    • Castilla La Mancha
      • Toledo, Castilla La Mancha, Spania, 45004
        • Hospital Virgen de la Salud
    • Castilla Y Leon
      • Salamanca, Castilla Y Leon, Spania, 37007
        • Hospital Universitario De Salamanca
    • Cataluña
      • Badalona, Cataluña, Spania, 08916
        • Institut Catalá d'Oncologia (ICO) BADALONA
      • Girona, Cataluña, Spania, 17007
        • Institut Català d'Oncologia (ICO) Girona
      • Hospitalet de Llobregat, Cataluña, Spania, 08908
        • Hospital Duran i Reynalds (ICO-Hospitalet)
    • Comunitat Valenciana
      • Valencia, Comunitat Valenciana, Spania, 46026
        • Hospital Universitario y Politécnico La Fe
    • Galicia
      • A Coruña, Galicia, Spania, 15009
        • Centro Oncologico de Galicia
      • Lugo, Galicia, Spania, 27003
        • Hospital Universitario Lucus Augusti
    • Islas Baleares
      • Palma De Mallorca, Islas Baleares, Spania, 07120
        • Hospital Universitario Son Espases
    • Navarra
      • Pamplona, Navarra, Spania, 31008
        • Complejo Hospitalario Navarra (PAMPLONA)
    • Tenerife
      • San Cristobal de la Laguna, Tenerife, Spania, 38320
        • Hospital Universitario Canarias (TENERIFE)

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Patients diagnosed with recurrent and/or metastatic SCCHN treated with a cetuximab plus paclitaxel regimen as first line for unresectable R/M disease, starting treatment with the defined cetuximab plus paclitaxel regimen, between January 2012 and December 2018 in 20 hospital members of the "Grupo Español de Tratamiento de Tumores de Cabeza y Cuello", who express consent to participate in the study or have not explicitly withheld consent for use of their data.

Beskrivelse

Inclusion Criteria:

  • Patients with histologically confirmed recurrent and/or metastatic head and neck squamous-cell carcinoma including oral cavity, oropharynx, hypopharynx and larynx.

Note: Histological confirmation is required at the diagnosis of the primary. Not for recurrence and/or metastatic stages when radiological or clinical confirmation is valid

  • Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.
  • Start of first cycle of paclitaxel plus cetuximab between 1 January 2012, and 31 December 2018.
  • Aged ≥ 18 years at the time of diagnosis of R/M SCCHN.

  • Voluntary written consent, if applicable*

    • Note: Waiver of consent could be acceptable after all reasonable efforts and procedures have been followed and exhausted, and when an explicit refusal to sign the informed consent or refusal for use of data, or a revocation of consent by the patient has not been obtained.

Exclusion Criteria:

  • Patients with histologically confirmed R/M SCCHN, who have also an unknown primary tumor or nasopharyngeal cancer or a non-squamous head & neck cancer.
  • Patients who received the paclitaxel and cetuximab regimen for the first time in recurrent and/or metastatic disease as a second or subsequent line.
  • Eastern Cooperative. Oncology Group (ECOG) performance status > 2.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Recurrent and/or metastatic SCCHN
Patients who received at least one dose of both paclitaxel 80 mg/m2 as a starting dose with weekly cetuximab, that could have been switched to biweekly during the maintenance phase, as a first line regimen in recurrent and/or metastatic disease.
Legemiddel: Cetuximab
Weekly cetuximab at starting dose, that could be switched to biweekly
Legemiddel: Paclitaxel
Paclitaxel at starting dose of 80 mg/m2

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-free survival (PFS)
Tidsramme: Through study completion, average 1 year
The PFS time is defined as the time from start of study treatment (first administration of cetuximab or paclitaxel) to the date of progression or death, whichever occurs first. In patients without a PFS event, the PFS time will be censored on the date of the last radiological evaluation or on the date of the last study treatment received if the tumor response has not been evaluated after start of study treatment. If no PFS was observed prior to start of second line treatment, then the PFS time will be censored at the first date of second line treatment.
Through study completion, average 1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Best Overall Response (BOR)
Tidsramme: Through study completion, average 1 year
Best overall response during study treatment with the categories complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) or not available (NA), as assessed by the responsible physician. The method used to assess BOR (e.g. RECIST and version) will be also recorded.
Through study completion, average 1 year
Overall Response Rate (ORR)
Tidsramme: Through study completion, average 1 year
Overall response rate, defined as the proportion of patients with CR or PR as BOR.
Through study completion, average 1 year
Disease Control Rate (DCR)
Tidsramme: Through study completion, average 1 year
The proportion of patients with CR, PR or SD as BOR.
Through study completion, average 1 year
Frequency of Adverse Events (AEs)
Tidsramme: Through study completion, average 1 year
Safety will be studied as function of AEs frequency: The number of adverse events classified by type and intensity
Through study completion, average 1 year
Overall survival (OS)
Tidsramme: Through study completion, average 1 year
Defined as time from start of study treatment until date of death due to any cause. In patients without death the OS time is censored at the last date known to be alive.
Through study completion, average 1 year
Relative dose intensity (RDI)
Tidsramme: Through study completion, average 1 year
Relative dose intensity (RDI) defined as amount of drug administered per unit of time expressed as the fraction of that defined in the standard regimen
Through study completion, average 1 year
Dose-related and compliance data
Tidsramme: Through study completion, average 1 year
Frequency and magnitude of dose interruptions, dose modifications and discontinuation of treatment classified by the cause of discontinuation including adverse events, relapse, medical decision, patient decision, death and loss of follow-up.
Through study completion, average 1 year
Duration of Response (DOR)
Tidsramme: Through study completion, average 1 year

Defined as the time from the first occurrence of PR or CR as BOR until PD or death, whichever occurs first in patients with CR or PR as BOR.

The censoring rules specified for PFS will be also applied for duration of response.
Through study completion, average 1 year
Proportion of long disease-free survivors
Tidsramme: Through study completion, average 1 year
The proportion of patients alive and disease-free at 2 years after start of study treatment. Only disease-free patients under first line treatment should be counted.
Through study completion, average 1 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Samarbeidspartnere

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Etterforskere

  • Hovedetterforsker: Beatriz Cirauqui Cirauqui, M.D. Ph.D., Institut Catalá d'Oncologia (ICO) BADALONA
  • Hovedetterforsker: Jordi Rubió Casadevall, M.D. Ph.D., Institut Català d'Oncologia (ICO) Girona

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. desember 2020

Primær fullføring (Faktiske)

17. januar 2022

Studiet fullført (Faktiske)

17. januar 2022

Datoer for studieregistrering

Først innsendt

11. desember 2020

Først innsendt som oppfylte QC-kriteriene

11. desember 2020

Først lagt ut (Faktiske)

17. desember 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. mars 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. mars 2022

Sist bekreftet

1. mars 2022

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • TTCC-2019-02
  • TTC-CET-2020-01 (Annen identifikator: Agencia Española del Medicamento y Productos Sanitarios)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere